MI Bioresearch is a technology company.
MI Bioresearch has raised $21.0M across 3 funding rounds.
MI Bioresearch has raised $21.0M in total across 3 funding rounds.
MI Bioresearch is a preclinical oncology contract research organization (CRO) specializing in in vivo and in vitro pharmacology services, including advanced imaging technologies for cancer drug development. Formerly known as Molecular Imaging, it provides a bank of human and syngeneic cancer cell line models, supported by platforms like MRI, micro-CT, micro-PET, SPECT, and optical imaging to evaluate sponsor drugs and biologics.[1][2][3] Based in Ann Arbor, Michigan, the company serves pharmaceutical and biotechnology firms by delivering decision-enabling data for preclinical and translational research, and it was acquired by Covance (a LabCorp subsidiary), integrating into a global drug development network.[2][4]
This positions MI Bioresearch as a key enabler in oncology R&D, offering comprehensive services from cell line models to focal beam radiation, with a focus on immuno-oncology models that address complex cancer pharmacology.[1][4]
Founded in 2003 in Ann Arbor, Michigan, MI Bioresearch (originally Molecular Imaging) emerged as a provider of in vivo pharmacology and imaging services tailored to oncology research.[1][3] Specific founders are not detailed in available records, but the company quickly built expertise in preclinical models, attracting early investment from Invest Detroit Ventures and others.[1] A pivotal moment came with its acquisition by Covance, a LabCorp subsidiary, which expanded its reach within a leading drug development ecosystem while preserving its specialized oncology focus.[2][4] This evolution from an independent entity to part of LabCorp's global network marked its growth from niche imaging services to a comprehensive CRO supporting diverse pharma clients.[4]
MI Bioresearch stands out in the preclinical CRO space through these key strengths:
MI Bioresearch rides the wave of surging oncology drug development, fueled by advances in immuno-oncology, biologics, and precision medicine, where preclinical accuracy is critical to reduce clinical failure rates.[1][4] Its timing aligns with market forces like rising R&D investments in cancer therapies—projected to exceed $200B annually by 2025—and the demand for imaging-enhanced models that bridge preclinical to clinical stages.[2][4] By influencing the ecosystem through high-fidelity data for sponsors, it accelerates pipelines for LabCorp clients, while ethical innovations like AI-driven animal welfare set standards in humane research, supporting broader trends in responsible biotech.[5]
MI Bioresearch is poised for expansion within LabCorp's ecosystem, likely integrating more AI and advanced imaging to tackle emerging challenges like multi-omics oncology models and personalized therapies. Trends such as accelerated drug approvals and AI-optimized preclinical testing will amplify its role, potentially evolving its influence toward leading global immuno-oncology CRO services. This builds on its core strength in delivering precise, ethical data that fast-tracks innovations from lab to patient.[5]
MI Bioresearch has raised $21.0M in total across 3 funding rounds.
MI Bioresearch's investors include Arboretum Ventures, Arcus Ventures, Beringea.
MI Bioresearch has raised $21.0M across 3 funding rounds. Most recently, it raised $4.0M Series B in October 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2013 | $4.0M Series B | Arboretum Ventures, Arcus Ventures, Beringea | |
| Mar 1, 2012 | $10.0M Series A | Arboretum Ventures, Arcus Ventures, Beringea | |
| May 1, 2011 | $7.0M Series A | Arboretum Ventures, Arcus Ventures, Beringea |